Sign inJoin waitlistJoin the waitlist

CA

Carol Aghajanian

Chief, Gynecologic Medical Oncology Service · New York Presbyterian Hospital

Credentials: · · · ·

History

Gynecologic Medical Oncology Service Division · New York Presbyterian Hospital
Present
New York Presbyterian Hospital
Present
New York Presbyterian Hospital
Present

Hematology and Medical Oncology
Memorial Sloan Kettering Cancer Center
1992–1995
Internal Medicine
Mount Sinai Hospital
1989–1992
SUNY Downstate College of Medicine
1985–1989

Research

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
New England Journal of Medicine · 2018 · 2,290 citations
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet · 2017 · 1,408 citations
OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian,…
Journal of Clinical Oncology · 2012 · First of 9 authors · Corresponding · 1,048 citations

NA
Nadeem Abu-Rustum
93 papers · 3 as a fellow
PS
Paul Sabbatini
75 papers
Dennis Chi
64 papers
DS
David Spriggs
61 papers
RO
Roisin O'Cearbhaill
59 papers
RG
Rachel Grisham
57 papers · 6 as a fellow
MH
Martee Hensley
55 papers
VM
Vicky Makker
52 papers
JK
Jason Konner
46 papers
WT
William Tew
42 papers
Dmitriy Zamarin
39 papers
RB
Richard Barakat
38 papers

Grants

Network Lead Academic Participating Site: Memorial Sloan Kettering Cancer Center
National Cancer Institute · UG1
Contact PI · $10.2M · Sloan-Kettering Inst Can Research
2019–2032
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
National Cancer Institute · U10
Contact PI · $4.6M · Sloan-Kettering Inst Can Research
2014–2019

Clinical trials

Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients
Principal investigator · Active not recruiting · Phase 3
AstraZeneca
2019–2026
A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer
Principal investigator · Completed · Phase 1
Memorial Sloan Kettering Cancer Center
2017–2025
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
Principal investigator · Active not recruiting · Phase 2
National Cancer Institute (NCI)
2009–2027
A Study of Tor Kinase Inhibitor in Advanced Tumors
Principal investigator · Completed · Phase 1
AstraZeneca
2008–2010